Editorial

Nuclear Medicine Communications

Volumn 24, Issue 9, 2003, Pages 945-950

  Van de Wiele, C ^a   Rottey, S ^a   Goethals, I ^a   Buscombe, J ^a   Van Belle, S ^a   De Vos, F ^a   Dierckx, R A ^a  

^a Divisions of Nuclear Medicine and Medical Oncology   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

BREAST TUMOR; CARCINOMA; DRUG RESISTANCE; DRUG THERAPY; EDITORIAL; HUMAN; LUNG TUMOR; METHODOLOGY; NEOPLASM; PROGNOSIS; SARCOMA; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY; HUMANS; LUNG NEOPLASMS; NEOPLASMS; PROGNOSIS; RADIOPHARMACEUTICALS; SARCOMA; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TREATMENT OUTCOME;

EID: 0842311838     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200309000-00001     Document Type: Editorial

References (28)

1. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I. Expression of a multidrug-resistance gene in human tumours and tissues. Proc Natl Acad Sci USA 1987; 84: 265-269.
2. Goldie JH, Goldman AJ. The genetic origin of drug resistance in neoplasms: implications for systemic therapy. Cancer Res 1984; 44: 3643-3653.
3. Hendrikse NH, Franssen EJF, van der Graaf WTA, Vaalburg W, de Vries EGE. Visualization of multidrug resistance in vivo. Eur J Nucl Med 1999; 26: 283-293.
4. Yamamoto Y, Nishiyama Y, Satoh K, et al. Comparative study of technetium-99m-sestamibi and thallium-201 SPECT in predicting chemotherapeutic response in small cell lung cancer. J Nucl Med 1998; 39: 1626-1629.
5. Kao CH, ChangLAi S, Chieng P, Yen T. Technetium-99m methoxyisobutylisonitrile chest imaging of small cell lung carcinoma. Cancer 1998; 83: 64-68.
6. Bom H, Kim Y, Song H, Min J, Kim J, Park K. Technetium-99m-MIBI uptake in small cell lung cancer. J Nucl Med 1998; 39: 91-94.
7. Bom H, Lim S, Kim Y, et al. Dipyridamole modulated Tc-99m sestamibi lung SPECT in small cell lung cancer. Clin Nucl Med 1999; 24: 97-101.
8. Kao C, Hsieh J, Tsai S, Ho Y, Lee J. Quickly predicting chemotherapy response to paclitaxel-based therapy in non-small cell lung cancer by early technetium-99m methoxyisobutylisonitrile chest single-photon-emission computed tomography. Clin Cancer Res 2000; 6: 820-824.
9. Nishiyama Y, Yamamoto Y, Satoh K, et al. Comparative study of Tc-99m MIBI and Tl-201 SPECT in predicting chemotherapeutic response in non-small-cell lung cancer. Clin Nucl Med 2000; 25: 364-369.
10. 99mTc-MIBI SPET in non-small cell lung cancer in relationship with Pgp and prognosis. Eur J Nucl Med 2002; 29: 876-881.
11. 99mTc-MIBI SPET. Eur J Nucl Med 2001; 28: 799-806.
12. Dirlik A, Burak Z, Goksel T, et al. The role of Tc-99m sestamibi imaging in predicting clinical response to chemotherapy in lung cancer. Ann Nucl Med 2002; 16: 103-108.
13. Ceriani L, Giovanella L, Bandera M, Beghe B, Ortelli M, Roncari G. Semi-quantitative assessment of Tc-99(m)-sestamibi uptake in lung cancer: relationship with clinical response to chemotherapy. Nucl Med Commun 1997; 18: 1087-1097.
14. Shiau Y, Tsai S, Wang J, Ho Y, Ho S, Kao C. To predict chemotherapy response using technetium-99m tetrofosmin and compare with p-glycoprotein and multidrug resistance related protein-1 expression in patients with untreated small cell lung cancer. Cancer Lett 2001; 169: 181-188.
15. 99mTc-tetrofosmin chest imaging. J Nucl Med 2001; 42: 17-20.
16. Kapucu L, Akyuz C, Vural A, Atasever T, Büyükpaukcu M, Unlü M. Evaluation of therapy response in children with untreated malignant lymphomas using technetium-99m-sestamibi. J Nucl Med 1997; 38: 243-247.
17. Kao C, Tsai S, Wang J, Ho Y, Ho S, Changlai S. Evaluation of chemotherapy response using technetium-99m-sestamibi scintigraphy in untreated adult malignant lymphomas and comparison with other prognosis factors: a preliminary report. Int J Cancer 2001; 95: 228-231.
18. Liang J, Shiau Y, Yang S, et al. Using technetium-99m-tetrofosmin scan to predict chemotherapy response of malignant lymphomas, compared with P-glycoprotein and multidrug resistance related protein expression. Oncol Rep 2002; 9: 307-312.
19. Ciarmiello A, Del Vecchio S, Silvestro P, et al. Tumor clearance of technetium 99m-sestamibi as a predictor of response to neo-adjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol 1998; 16: 1677-1683.
20. 99mTc-sestamibi washout in predicting response of locally advanced breast cancer to neo-adjuvant chemotherapy. J Nucl Med 2002; 43: 745-751.
21. 99mTc-MIBI uptake. Nucl Med Commun 2002; 23: 31-38.
22. 99mTc sestamibi scintigraphy in the evaluation of doxorubicin based chemotherapy response in patients with advanced breast cancer. Nucl Med Commun 2002; 23: 765-771.
23. 99mTc-sestamibi scintimammography predicts response to neo-adjuvant chemotherapy and is related to MDR expression. Int J Oncol 2002; 20: 1049-1055.
24. Takamura Y, Miyoshi Y, Taguchi T, Shinzaburo N. Prediction of chemotherapeutic response by technetium 99m-MIBI scintigraphy in breast carcinoma patients. Cancer 2001; 2: 232-239.
25. Kim R, Osaki A, Hirai T, Toge T. Utility of technetium-99m methoxyisobutyl isonitrile uptake analysis for prediction of the response to chemotherapy in advanced and relapsed breast cancer. Breast Cancer 2002; 9: 240-247.
26. Takeuchi N, Mitsutaka F, Nishioka A, et al. Scintigraphic prediction of response to chemotherapy in patients with breast cancer: technetium 99m-tetrofosmin and thallium-201 dual single photon emission computed tomography. Int J Oncol 2002; 20: 53-58.
27. 99mTc-MIBI scintigraphy in the assessment of MDR1 overexpression in patients with musculoskeletal sarcomas: comparison with therapy response. Eur J Nucl Med 2001; 28: 1341-1350.
28. Gorlick R, Liao AC, Antonescu C, et al. Lack of correlation of functional scintigraphy with technetium-99m methoxyisobutylisonitrile with histological necrosis following induction chemotherapy or measures of p-glycoprotein expression in high-grade osteosarcoma. Clin Cancer Res 2001; 7: 3065-3070.